Indication
Add-on therapy for children (6y+), adolescents, and adults with severe refractory eosinophilic asthma

Medicine details

Medicine name:
mepolizumab (Nucala)
SMC ID:
SMC2139
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated submission
Status
Advice due date:
08 April 2019
SMC meeting date:
05 March 2019